Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abayneh M, Tesfaw G, Abdissa A (2018) Isolation of extended-spectrum β-lactamase-(ESBL-) producing Escherichia coli and Klebsiella pneumoniae from patients with community-onset urinary tract infections in Jimma University Specialized Hospital, Southwest Ethiopia. Can J Infect Dis Med Microbiol 2018:4846159
Albaramki J, Abdelghani T, Dalaeen A, Khdair Ahmad F, Alassaf A, Odeh R (2019) Urinary tract infection caused by ESBL-producing bacteria: risk factors and antibiotic resistance. Pediatr Int 61(11):1127–1132
Amladi AU, Abirami B, Devi SM, Sudarsanam TD, Kandasamy S, Kekre N, Veeraraghavan B, Sahni RD (2019) Susceptibility profile, resistance mechanisms & efficacy ratios of fosfomycin, nitrofurantoin & colistin for carbapenem-resistant Enterobacteriaceae causing urinary tract infections. Indian J Med Res 149:185
Behzadi P, Urbán E, Matuz M, Benkő R, Gajdács M (2021) The role of gram-negative bacteria in urinary tract infections: current concepts and therapeutic options. Adv Exp Med Biol 1323:35–69
Bharadwaj R, Robinson ML, Balasubramanian U, Kulkarni V, Kagal A, Raichur P, Khadse S, Kadam D, Valvi C, Kinikar A (2018) Drug-resistant Enterobacteriaceae colonization is associated with healthcare utilization and antimicrobial use among inpatients in Pune, India. BMC Infect Dis 18:504
Chander A, Shrestha CD (2013) Prevalence of extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae urinary isolates in a tertiary care hospital in Kathmandu, Nepal. BMC Res Notes 6:487
CLSI (2017) Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute, Wayne
CLSI (2018) Performance standards for antimicrobial susceptibility testing. CLSI supplement M100, 28th edn. Clinical and Laboratory Standards Institute, Wayne
David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, Abudahab K, Goater R, Giani T, Errico G (2019) Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat Microbiol 4:1919–1929
Dayan N, Dabbah H, Weissman I, Aga I, Even L, Glikman D (2013) Urinary tract infections caused by community-acquired extended-spectrum β-lactamase-producing and nonproducing bacteria: a comparative study. J Pediatr 163:1417–1421
De La Blanchardière A, Dargère S, Guérin F, Daurel C, Saint-Lorant G, Verdon R, Cattoir V (2015) Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae. Med Mal Infect 45:169–172
Eshetie S, Unakal C, Gelaw A, Ayelign B, Endris M, Moges F (2015) Multidrug resistant and carbapenemase producing Enterobacteriaceae among patients with urinary tract infection at referral hospital, Northwest Ethiopia. Antimicrob Resist Infect Control 4:12
Fernando M, Luke W, Miththinda J, Wickramasinghe R, Sebastiampillai B, Gunathilake M, Silva F, Premaratna R (2017) Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern – a hospital based cross sectional study. BMC Infect Dis 17:138
Flateau C, Duron-Martinaud S, Haus-Cheymol R, Bousquet A, Delaune D, Ficko C, Merens A, Rapp C (2018) Prevalence and risk factors for extended-spectrum beta-lactamase-producing-Enterobacteriaceae in French military and civilian travelers: a cross-sectional analysis. Travel Med Infect Dis 23:44–48
Flokas ME, Karanika S, Alevizakos M, Mylonakis E (2017) Prevalence of ESBL-producing Enterobacteriaceae in pediatric bloodstream infections: a systematic review and meta-analysis. PLoS One 12:e0171216
Gajdács M (2019) The concept of an ideal antibiotic: implications for drug design. Molecules 24:892
Gajdács M (2020) The importance of reporting clinical and epidemiological data in urology: local experiences and insights from the international literature. Medicina 56:581
Gajdács M, Ábrók M, Lázár A, Burián K (2019) Comparative epidemiology and resistance trends of common urinary pathogens in a tertiary-care hospital: a 10-year surveillance study. Medicina 55:356
Gajdács M, Ábrók M, Lázár A, Jánvári L, Tóth Á, Terhes G, Burián K (2020a) Detection of VIM, NDM and OXA-48 producing carbapenem resistant Enterobacterales among clinical isolates in southern Hungary. Acta Microbiol Immunol Hung 67:209–215
Gajdács M, Bátori Z, Ábrók M, Lázár A, Burián K (2020b) Characterization of resistance in gram-negative urinary isolates using existing and novel indicators of clinical relevance: a 10-year data analysis. Life 10:16
Gashaw M, Berhane M, Bekele S, Kibru G, Teshager L, Yilma Y, Ahmed Y, Fentahun N, Assefa H, Wieser A (2018) Emergence of high drug resistant bacterial isolates from patients with health care associated infections at Jimma University medical center: a cross sectional study. Antimicrob Resist Infecti Control 7:138
Hassan H, Abdalhamid B (2014) Molecular characterization of extended-spectrum beta-lactamase producing Enterobacteriaceae in a Saudi Arabian tertiary hospital. J Infect Dev Ctries 8:282–288
Kiddee A, Assawatheptawee K, Na-Udom A, Boonsawang P, Treebupachatsakul P, Walsh TR, Niumsup PR (2019) Risk factors for extended-spectrum β-lactamase-producing Enterobacteriaceae carriage in patients admitted to intensive care unit in a tertiary care hospital in Thailand. Microb Drug Resist 25:1182–1190
Legese MH, Weldearegay GM, Asrat D (2017) Extended-spectrum beta-lactamase-and carbapenemase-producing Enterobacteriaceae among Ethiopian children. Infect Drug Resist 10:27
Nakai H, Hagihara M, Kato H, Hirai J, Nishiyama N, Koizumi Y, Sakanashi D, Suematsu H, Yamagishi Y, Mikamo H (2016) Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. J Infect Chemother 22:319–326
Okoche D, Asiimwe BB, Katabazi FA, Kato L, Najjuka CF (2015) Prevalence and characterization of carbapenem-resistant Enterobacteriaceae isolated from Mulago National Referral Hospital, Uganda. PLoS One 10:e0135745
Ouedraogo AS, Sanou M, Kissou A, Sanou S, Solare H, Kabore F, Poda A, Aberkane S, Bouzinbi N, Sano I, Nacro B, Sangare L, Carriere C, Decre D, Ouegraogo R, Jean-Pierre H, Godreuil S (2016) High prevalence of extended-spectrum ss-lactamase producing enterobacteriaceae among clinical isolates in Burkina Faso. BMC Infect Dis 16:326
Pishtiwan AH, Khadija KM (2019) Prevalence of blaTEM, blaSHV, and blaCTX-M genes among ESBL-producing Klebsiella pneumoniae and Escherichia coli isolated from thalassemia patients in Erbil, , Iraq. Mediterr J Hematol Infect Dis 11:e2019041
Rao MR, Chandrashaker P, Mahale RP, Shivappa SG, Gowda RS, Chitharagi VB (2019) Detection of carbapenemase production in Enterobacteriaceae and pseudomonas species by carbapenemase Nordmann–Poirel test. J Lab Phys 11:107
Reuland E, Al Naiemi N, Kaiser A, Heck M, Kluytmans J, Savelkoul P, Elders P, Vandenbroucke-Grauls C (2016) Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in Amsterdam. J Antimicrob Chemother 71:1076–1082
Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A (2018) Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing. Enterobacteriaceae CMR 31(2):e00079–e00017
Saliu EM, Vahjen W, Zentek J (2017) Types and prevalence of extended-spectrum beta-lactamase producing Enterobacteriaceae in poultry. Anim Health Res Rev 18:46–57
Selassie LG (2016) Prevalence of extended spectrum beta-lactamase producing Enterobacteriaceae: a cross sectional study at Adama Hospital, Adama, Ethiopia. J Emerg Infect Dis 1:102
Singh N, Pattnaik D, Neogi DK, Jena J, Mallick B (2016) Prevalence of ESBL in Escherichia coli isolates among ICU patients in a tertiary care hospital. J Clin Diagn Res 10:DC19–DC22
Tamadonfar KO, Omattage NS, Spaulding CN, Hultgren SJ (2019) Reaching the end of the line: urinary tract infections. Bacteria Intracellularity 7(3): 83–99
Teklu DS, Negeri AA, Legese MH, Bedada TL, Woldemariam HK, Tullu KD (2019) Extended-spectrum beta-lactamase production and multi-drug resistance among Enterobacteriaceae isolated in Addis Ababa, Ethiopia. Antimicrob Resist Infect Control 8:39
Vandepitte J, Verhaegen J, Engbaek K, Rohner P, Piot P, Heuck C, Heuck C (2003) Basic laboratory procedures in clinical bacteriology. World Health Organization, Geneva
Woodford N, Xu-Mccrae L, Mushtaq S, Wu HHT, Ellington MJ, Lancaster O, Davies F, Donaldson H, Rao GG, Verma A (2018) Prevalence of carbapenem resistance and carbapenemase production among Enterobacteriaceae isolated from urine in the UK: results of the UK infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-UK). J Antimicrob Chemother 73:698–702
Acknowledgments
The authors would like to thank TASH laboratory staffs for their well coming approach during the laboratory work and the study participants.
Author Contributions
All authors made a significant contribution to the work reported, Data acquisition, analysis and interpretation: SS and TA. Revising critically and Final approval: BY, AA, DA, TA and AM. All authors gave final approval of the version to be published
Dataset
The datasets supporting the conclusions of this article are included within the article and its additional files
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Seman, A. et al. (2021). The Magnitude of Carbapenemase and ESBL Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections at Tikur Anbessa Specialized Teaching Hospital, Addis Ababa, Ethiopia. In: Donelli, G. (eds) Advances in Microbiology, Infectious Diseases and Public Health. Advances in Experimental Medicine and Biology(), vol 1369. Springer, Cham. https://doi.org/10.1007/5584_2021_687
Download citation
DOI: https://doi.org/10.1007/5584_2021_687
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-01994-4
Online ISBN: 978-3-031-01995-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)